Clinical Trials
Discover the future of medicine today. Yale Medicine currently offers 687 active clinical trials across our hospitals and care centers, providing our patients with early access to many of the world’s most advanced therapies. Yale Center for Clinical Investigation (YCCI) supports, coordinates, and oversees clinical trials, ensuring the safety of trial volunteers.
For more information about cancer-related trials, call us at 203-785-5702. For all other trials, call 877-978-8343.
39 Results
A Phase 1 Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors
- Phase 1 Cancers
A Phase 1, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL217 in Patients With Advanced Solid Tumors
- Phase 1 Cancers
A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bomedemstat (MK-3543) Versus Hydroxyurea in Cytoreductive Therapy Naïve Essential Thrombocythemia Participants
- Leukemia & Hematologic Cancers
AACR Adaptive Biomarker-Driven Organ Preservation Trial In Gastroesophageal Adenocarcinomas (AACR-ADOPT-GEA)
- Stomach & Esophagus
Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
- Thyroid & Other Endocrine Cancers
- Pancreatic Cancer
A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s)
- Phase 1 Cancers
A Platform Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- Colorectal Cancer
- Pancreatic Cancer
A Phase 3, Randomized, Multicenter, Open-Label Study of Velzatinib (GSK6042981) Versus Imatinib in Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST)
- Colorectal Cancer
- Sarcoma Cancers
- Stomach & Esophagus
Phase II Prospective, Open Label Randomized Controlled Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
- Stomach & Esophagus
- Liver Cancer
- Gastrointestinal Cancers
- Pancreatic Cancer
- Colorectal Cancer
Short TeRm Intensified Pembrolizumab (KEytruda) and Tivozanib for High-Risk Renal Cell Carcinoma - STRIKE
- Kidney Cancer
1-10 of 39 Results